BrainStorm wins additional US patent for its autologous stem cell technology
M2 - Fri Apr 11, 7:31AM CDT
US-based stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI) revealed on Thursday the receipt of an additional patent for its autologous stem cell technology.
BrainStorm Granted Additional US Patent for Its Autologous Stem Cell Technology
Marketwire - Thu Apr 10, 8:36AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company an additional patent for its autologous stem cell technology. The patent (No. 8,647,874) covers the production method of the company's proprietary stem cells induced to secrete significantly elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
Marketwire - Tue Mar 25, 5:01AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals. The other two clinical sites slated for the multi-center trial are the University of Massachusetts Memorial (UMass) Hospital and Mayo Clinic. Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture the NurOwn cells for MGH and UMass Hospital.
BrainStorm Granted Key US Patent for Its Autologous Stem Cell Technology
Marketwire - Mon Mar 24, 5:29AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company a key patent for its autologous stem cell technology. The patent (No. 8,663,987) covers BrainStorm's proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
Amber Road Makes Market Debut; Tranzbyte Corporation Signs LOI with Abattis
ACCESSWIRE - Sun Mar 23, 11:30PM CDT
Amber Road, Inc. (NYSE: AMBR) - For an in-depth report on Amber Road, Inc. follow: www.BullTrends.com/stockquote/AMBR
BrainStorm to Present Latest Company Developments at Regen Med Investor Day March 26 in New York
Marketwire - Tue Mar 18, 8:45AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Mr. Chen Schor, Executive Board Member, will present the company's latest developments at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
BrainStorm Cell Therapeutics awarded USD600,000 non-dilutive grant
M2 - Wed Feb 26, 5:59AM CST
Stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI), based in the US and Israel, disclosed on Tuesday the receipt of an additional USD600,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014.
BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist
Marketwire - Tue Feb 25, 8:15AM CST
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that BrainStorm Cell Therapeutics Ltd. was awarded an additional non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014 in the amount of $600,000. The grant is intended to support BrainStorm's clinical development for its innovative stem cell therapy candidate NurOwn(TM).
BrainStorm Issues Annual Letter to Shareholders
Business Wire - Tue Feb 04, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today issued a Letter to Shareholders from its President, Mr. Chaim Lebovits, summarizing the company's major developments in 2013.
BrainStorm Receives US Notice of Allowance for its Key Stem Cell Technology Patent
Business Wire - Mon Feb 03, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Mesenchymal Stem Cells for the Treatment of CNS Diseases" (serial number 12/994,761) patent application.
BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing
Business Wire - Wed Jan 29, 7:00AM CST
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA approval. In addition, Mayo's Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The other two sites slated for the multi-center trial are the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.
BrainStorm Hosting a Conference Call with Clinical Trial Advisors in Israel, US and Brazil to Update Shareholders on Current Developments
Business Wire - Wed Jan 15, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Thursday, January 30, 2014 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST).
BrainStorm Cell Therapeutics awarded US Patent Office's Notice of Allowance for stem cell technology
M2 - Tue Jan 14, 4:51AM CST
Biotechnology company BrainStorm Cell Therapeutics (OTC BB:BCLI) reported on Monday the receipt of a Notice of Allowance for its 'Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases'.
BrainStorm Receives United States Patent Office Notice of Allowance for Its Stem Cell Technology
Business Wire - Mon Jan 13, 8:42AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application.
BrainStorm Receives Notice of Allowance to Grant European Patent Covering its Stem Cells for the Treatment of CNS Diseases
Business Wire - Wed Jan 08, 8:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received notification from the European Patent Office (EPO) of its intention to grant the company's patent application No. EP06766101.7 entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases."
Significant Clinical Findings on ALS Patient Treated with BrainStorm's NurOwn Featured in "Muscle and Nerve"
Business Wire - Mon Jan 06, 7:30AM CST
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced the upcoming publication of a case report on an individual patient treated with the company's NurOwn(TM) cell therapy in "Muscle & Nerve" (John Wiley & Sons). The report, which looked at one patient diagnosed with both Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS) showed significant improvements in both cognitive and motor function following initial and repeat treatments with NurOwn.